Qiagen NV (QGEN) PT Raised to $58 at Cowen

Cowen analyst Dan Brennan raised the price target on Qiagen NV (NYSE: QGEN) to $58.00 (from $55.00) while maintaining a Market Perform rating.

The analyst commented, "COVID upside drove a 3Q beat while underlying base growth was shy of our forecast and decelerated on a stack (with 4Q implying a further stack deceleration). The '22 outlook continues to call for solid '22 base growth, though we trimmed our outlook. Investor attention has shifted to potential for strategic activity given recent news, with commentary here limited. Remain Market Perform, PT to $58."

You May Also Be Interested In

• JPMorgan Upgrades Banco BPM SpA (BAMI:IM) (BNCZF) to Neutral
• JPMorgan Upgrades Carnarvon Petroleum Ltd. (CVN:AU) (CVONF) to Overweight
• Canaccord Genuity Upgrades Blackline Safety Corp (BLN:CN) (BLKLF) to Buy